Gülşen Yılmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gülşen Yılmaz has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Can Kutlay
Thoracic Surgery Department, Ankara Etlik Şehir Hastanesi, Ankara, Türkiye
2 shared publications - Selim Şakir Erkmen Gülhan
Thoracic Surgery Department, Ankara Atatürk Sanatoryum Eğitim ve Araştırma Hastanesi, Ankara, Türkiye
2 shared publications - Seray Hazer
UNIVERSITY OF HEALTH SCIENCES, ANKARA ATATÜRK HEALTH RESEARCH CENTER FOR PULMONOLOGY AND THORACIC SURGERY
2 shared publications - Aslıhan Alhan
Ufuk University Faculty of Medicine, Department of Biostatistics, Ankara, Turkey
1 shared publication - Göktürk Fındık
Department of Thoracic Surgery, Atatürk Sanatoryum Training and Research Hospital, Ankara, Turkey
1 shared publication - Koray Aydoğdu
Department of Thoracic Surgery, Ankara Etlik City Hospital, Ankara, Turkey
1 shared publication
Latest Publications
- 21 August 2026
- Published by Springer Nature in Indian Journal of Surgery
- p. 1-11
Pulmonary Sarcomatoid Carcinoma: Updated Analysis on Prognostic Factors Influencing Diagnosis and Survival
- 21 August 2026
- Published by Springer Nature in Indian Journal of Surgery
- p. 1-11
Pulmonary Sarcomatoid Carcinoma: Updated Analysis on Prognostic Factors Influencing Diagnosis and Survival
- 29 July 2026
- Published by Springer Nature in Surgery Today
- Vol. 56 (11) , 2927-2938
Outcomes after esophageal perforation: A tertiary referral center series
- 29 July 2026
- Published by Springer Nature in Surgery Today
- Vol. 56 (11) , 2927-2938
Outcomes after esophageal perforation: A tertiary referral center series
- Open Access
- 23 May 2024
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 2 (2) , 42-44
Pulmonary aspergillosis after COVID-19, a case report
COVID-19 is an infectious disease that spreads worldwide, can progress rapidly, affect individuals of all ages, and cause death, especially in the elderly and people with chronic diseases. It has predisposed a relatively high number of patients to acute respiratory distress syndrome, and co-infections are a frequent complication, especially during prolonged hospital stays. Bacterial or viral co-infections with SARS-CoV-2 have been reported in many studies, but knowledge of Aspergillus co-infection in patients with COVID-19 is limited. This study presents a 57-year-old male patient with COVID-19 who had had no lung disease before COVID-19 pneumonia. However, after COVID-19 pneumonia with sequels and treatments that include corticosteroids and IL-6 receptor antagonists, an invasive pulmonary aspergillus (IPA) cavity occurred immediately. In addition to the fact that COVID-19 infection progresses with destructive parenchymal damage and sequelae, the effectiveness of treatment is limited, and treatment-related side effects and complications can be examined. Therefore, clinical and radiological follow-up of patients whose symptoms persist after infection is essential.
- 23 May 2024
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 2 (2) , 42-44
Open AccessPulmonary aspergillosis after COVID-19, a case report
COVID-19 is an infectious disease that spreads worldwide, can progress rapidly, affect individuals of all ages, and cause death, especially in the elderly and people with chronic diseases. It has predisposed a relatively high number of patients to acute respiratory distress syndrome, and co-infections are a frequent complication, especially during prolonged hospital stays. Bacterial or viral co-infections with SARS-CoV-2 have been reported in many studies, but knowledge of Aspergillus co-infection in patients with COVID-19 is limited. This study presents a 57-year-old male patient with COVID-19 who had had no lung disease before COVID-19 pneumonia. However, after COVID-19 pneumonia with sequels and treatments that include corticosteroids and IL-6 receptor antagonists, an invasive pulmonary aspergillus (IPA) cavity occurred immediately. In addition to the fact that COVID-19 infection progresses with destructive parenchymal damage and sequelae, the effectiveness of treatment is limited, and treatment-related side effects and complications can be examined. Therefore, clinical and radiological follow-up of patients whose symptoms persist after infection is essential.
- Open Access
- 31 January 2024
- Published by Wiley
Pulmonary Aspergillosis After Covid-19, A Case Report
This study presents a 57-year-old male patient with COVID-19 who had had no lung disease before COVID-19 pneumonia. However, after COVID-19 pneumonia with sequels and treatments that include corticosteroids and IL-6 receptor antagonists, an invasive pulmonary aspergillus (IPA) cavity occurred immediately.
- 31 January 2024
- Published by Wiley
Open AccessPulmonary Aspergillosis After Covid-19, A Case Report
This study presents a 57-year-old male patient with COVID-19 who had had no lung disease before COVID-19 pneumonia. However, after COVID-19 pneumonia with sequels and treatments that include corticosteroids and IL-6 receptor antagonists, an invasive pulmonary aspergillus (IPA) cavity occurred immediately.